Amid biosimilar competition, Genentech recalls next-generation eye treatment

Drug developers have dived into wet age-related macular degeneration — one of the leading causes of blindness — but so, too, have makers of lower-cost biosimilars.

Source: bizjournals.com Health Care:Biotechnology headlines - October 19, 2022 Category: Biotechnology Authors: Ron Leuty Source Type: news